Temenos SaaS Supports Flowe in Launching an Ethical Challenger Bank in Record Time
7.10.2020 10:30:00 EEST | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, today announced that Banca Mediolanum Group’s digital bank, Flowe, has gone live with Temenos Transact and Financial Crime Mitigation (FCM) delivered as SaaS. Temenos Transact core banking technology enabled Flowe to launch in just five months as Italy’s newest challenger bank aiming to disrupt the market with sustainable and ethical financial services. Flowe launched in record time on Temenos SaaS after a remote implementation during the coronavirus pandemic.
Flowe launched in June 2020 to meet the needs of younger retail banking customers who desire ethical and innovative digital banking. The digital bank provides user-friendly mobile banking experiences and aims to be more eco-friendly than traditional banks. With Temenos SaaS technology, Flowe has the agility required to bring new products to market faster and offer the personalized experiences that customers need. Temenos SaaS combined with the unique ability of the underlying technologies of Temenos Transact will enable Flowe to launch new products at a fraction of the time and differentiate the customer experience.
Flowe provides an account with an Italian IBAN without monthly fees, with the Fun account; ATM withdrawals in the Eurozone are free and the maximum account balance is €10,000. The Flowe card is made from wood that comes from certified forests and it supports reforestation in Guatemala, reduces and offsets CO2 emissions and supports local families. The bank encourages social wellbeing and builds community by enabling users to share expenses. The challenger offers 100% facial recognition onboarding and it is naturally paperless in its operations. Temenos’ API-first technology allows Flowe to cut down deployment time and costs as well as easily connect to third parties. This means that the bank can continuously innovate and update its product lines to meet the changing needs of its audience of young banking consumers.
Temenos SaaS technology enabled the bank to rapidly launch, it offers elastic scalability to support Flowe’s client growth and it dramatically reduces IT costs. Flowe has created a hyper-efficient business model based on Temenos SaaS technology, which enables Flowe to pass on the benefits to its customers.
Temenos’ AI-driven FCM offers the most complete protection against financial crime to improve resiliency and customer experience despite rising cybercrime rates due to coronavirus. Flowe will implement Temenos Payments later this year to provide instant payments in response to heightened demand. Temenos Payments will be integrated with Temenos Transact to provide seamless user experiences and market-leading cost-income ratios.
Temenos worked closely with Flowe to support a remote implementation during the coronavirus pandemic. Temenos’ SaaS technology on Microsoft Azure accelerated the project timelines so that Flowe could launch in five months and address the surge in demand for digital banking. Temenos’ Italy Model Bank provided highly localized, pre-configured banking functionality so Flowe could deploy the technology as is, without customization.
Ivan Mazzoleni, Chief Executive Officer, Flowe, commented: “We are excited to announce this strategic partnership with Temenos. Its cutting-edge technology powered our launch and now fuels our purpose to bring a new standard of sustainable banking to the European market. Temenos’ focus and unparalleled investment in innovation means Flowe will continue to benefit from the most advanced banking technology. Temenos’ SaaS technology helped us to rapidly onboard a significant number of users in a matter of days. It will continue to support our growth as we expand our customer-base and reach new markets but mainly, it will help us in our scope that is empowering people to live a meaningful, sustainable and happy life. Temenos’ open and API-first architecture will help us to continuously innovate and bring to market greener banking products and services as we build our reputation as Italy’s most sustainable digital bank.”
Max Chuard, Chief Executive Officer, Temenos, added: “Congratulations to Flowe for making this inspirational vision for a sustainable financial lifestyle a reality – we are proud to support them. Our partnership with Flowe shows the power of cloud technology and the benefits of SaaS. Temenos Transact and Temenos Financial Crime Mitigation products were remotely delivered as SaaS allowing Flowe to reap the benefits of scalability, efficiency and an elastic cost structure. Temenos is proud to support global digital banks like Flowe as they challenge the status quo and digitalize banking at pace. Temenos market-leading technology and rich expertise means that new digital banks and larger incumbents can gain the agility to innovate and grow, without the restrictions of legacy technology.”
According the recent research from The Economist Intelligence Unit, building a greenfield digital bank remains a top innovation strategy according to 35% of global bank executives.
– Ends –
About Flowe
Flowe is a newly created Benefit, pending BCorp and Carbon Neutral company of Mediolanum Group, which aims to educate young people on the issues of innovation and economic, social and environmental sustainability. In this era of infinite possibilities, where younger generations often feel uncertain about their future and unable to choose a direction, Flowe wants to give young people all the methods and tools to develop their potential and live better. Through its mobile app and the growing ecosystem of partners, Flowe aims to build a BetterBeing Economy to help young people live a more meaningful, sustainable and happy life.
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201007005045/en/
Contact information
Jessica Wolfe & Scott Rowe
Temenos Global Public Relations
Tel: +1 610 232 2793 & +44 20 7423 3857
Email: press@temenos.com
Annachiara Haerens
Flowe Public Relations
Tel: 39 3494794125
Email: annachiara.haerens@flowe.com
Alistair Kellie & Andrew Adie
Newgate Communications on behalf of Temenos
Tel: +44 20 7680 6550
Email: allnewgatetemenos@newgatecomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
